RNAi research blooms with yeast-based production

By Maggie Lynch contact

- Last updated on GMT

RNAi research blooms with yeast-based production

Related tags: Rna, RNAi, Rna interference, Collaboration, Yeast, Research and development, Biotherapeutics

Renaissance BioScience enters a partnership with Mitacs to test its yeast-based, RNAi production platform for biocontrol and biotherapeutics applications.

The University of British Columbia, Mitacs, and the University of Manitoba will join Renaissance BioScience Corporation (RBSC) in a three-year $975,000 CDN ($741,750), multi-investigator research and development project.

Mitacs will provide matching funding for the RBSC project to extend its research and development of an engineered, yeast-based RNA interference (RNAi) production and delivery platform across insect and animal models.

The tests performed and funded in this partnership will confirm the proof-of-concept utility for the yeast-based system. This system may then be able to augment industrial chemical pesticides of an animal and human biotherapeutics production and delivery platforms.

Mitacs CEO and scientific director Alejandro Adem said that yeast-based RNAi therapeutics is an emerging area of research and Canada has the opportunity to become a world leader in it.

Matthew Dahabieh, CSO of RBSC, said in a statement, “There is a significant potential global market, for these environmentally friendly, RNAi-based technologies, especially in the crop protection and animal agricultural sectors.”

He further stated, “Up until now, the efficient and cost-effective delivery of RNAi in the field has always been a barrier to adoption. Yeast, however, as a stable, non-toxic and well-understood industrial organism, is an excellent platform to deliver on the promise of RNAi as a biocontrol and medical biotherapeutics agent.”​ 

RNAi: An emerging area itself

In August 2018, Alnylam’s Onpattro (patisiran) was the first RNAi therapeutic treatment to be approved​ by the US Food and Drug Administration (FDA).

RNAi itself is still being researched and is an emerging area for therapeutic development. Research has shown that it can be applied to treatments for viral infections, cancers, and neurological diseases based on its programmed target.

Related news

Show more

Related products

Connectivity & Integration in Biomanufacturing

Connectivity & Integration in Biomanufacturing

Wheeler Bio | 17-Nov-2022 | Technical / White Paper

As the Pharma 4.0 initiative sets a new industry paradigm, more biomanufacturing companies are asking how they can design and build facilities that apply...

Scalability, Quality, and Speed with Transposons

Scalability, Quality, and Speed with Transposons

Wheeler Bio | 20-Oct-2022 | Technical / White Paper

To solve for the significant bottlenecks often presented by conventional cell line development processes, this article discusses how Wheeler Bio is leveraging...

Accelerating Time to IND with Pharma 4.0

Accelerating Time to IND with Pharma 4.0

Wheeler Bio | 22-Sep-2022 | Technical / White Paper

The future of the biopharmaceutical industry hinges on its adoption of 21st-century digital tools and automation.

Discover the world of upstream bioprocessing

Discover the world of upstream bioprocessing

Eppendorf Bioprocess Solutions | 07-Sep-2022 | Technical / White Paper

A must-read for all bioprocess scientists: This bundle of four ebooks created by Eppendorf guides you through the world of upstream bioprocessing.

Related suppliers

Follow us

Products

View more

Webinars